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Amyloid betaBrain-derived neurotrophic factor (BDNF) stimulation of its high-afﬁnity receptor TrkB results in activation of
pro-survival cell-signalling pathways that can afford neuroprotection to the retina. Reduction in retrograde axo-
nal transport of neurotrophic factors such as BDNF from the brain to the neuronal cell bodies in the retina has
been suggested as a critical factor underlying progressive and selective degeneration of ganglion cell layer and
optic nerve in glaucoma. We investigated the role of BDNF in preserving inner retinal homeostasis in normal
and glaucoma states using BDNF+/− mice and compared it with wild type controls. This study demonstrated
that BDNF+/− animals were more susceptible to functional, morphological and molecular degenerative changes
in the inner retina caused by age as well as upon exposure to experimental glaucoma caused by increased
intraocular pressure. Glaucoma induced a down regulation of BDNF/TrkB signalling and an increase in levels of
neurotoxic amyloid β 1–42 in the optic nerve head which were exacerbated in BDNF+/−mice. Similar results
were obtained upon analysing the human optic nerve head tissues. Our data highlighted the role of BDNF in
maintaining the inner retinal integrity under normal conditions and the detrimental effects of its insufﬁciency
on the retina and optic nerve in glaucoma.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Retinal ganglion cell (RGC) degeneration and associated optic nerve
head (ONH) excavation are characteristic features of glaucomawhich is
a neurodegenerative disorder associated with progressive loss of the vi-
sual ﬁeld. RGC axons converge at the ONH and form the optic nerve. A
strong genetic basis of the disease predisposition is supported in several
studies [1,2]. Elevated intraocular pressure (IOP) is the prominent risk
factor in primary open angle glaucoma which is the most common
form [3]. Exposure to high IOP is believed to promote RGC loss and
ONH cupping by several possible mechanisms including chronicr; TrkB, tropomyosin related ki-
ptic nerve head; GCL, ganglion
anglion cells; IOP, intraocular
retinogram; pSTR, positive sco-
edMedicine, 75, Talavera Road,
+61 298502760.ischemia and disruption of axoplasmic ﬂow with sequestration or ob-
struction of the support of neurotrophic factors [4,5]. Many studies
have reported that brain-derived neurotrophic factor (BDNF) in partic-
ular, plays a vital role inmaintaining the health of RGCs in the retina and
protecting them from apoptosis [6–10]. BDNF stimulates the growth of
neurites from regenerating RGCs [11], and can protect optic nerve (ON)
axons and RGCs from damage in various models of ON injury [10,12–
14]. The neurotrophic effects of BDNF are primarily mediated through
its high-afﬁnity receptor, tropomyosin receptor kinase B (TrkB), which
upon stimulation undergoes dimerization and phosphorylation of its
critical intracellular tyrosine residues. Both BDNF and TrkB have been
shown to be present in the retina and widely expressed in the RGCs
[15,16] and lamina cribrosa [17]. Activation of TrkB leads to the activa-
tion of the downstream Akt and extracellular signal-regulated kinases
1 and 2 (Erk1/2) [18,19] which promote different cellular signalling
pathways linked to growth, differentiation and survival [20,21].
BDNF is produced locally by RGCs [22] and astrocytes in the retina
[23], but it is also synthesised in the superior colliculus and the lateral
geniculate nucleus in higher mammals from where it is retrogradely
transported via RGC axons to the cell bodies [24]. When IOP was exper-
imentally elevated in rats and monkeys, retrograde transport of the
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the ONH [25,26]. Deprivation of BDNF supply to RGCs thus caused by
disruption in retrograde transport may contribute to neuronal loss in
glaucoma [25]. Supporting these observations, exogenous application
of BDNF has been shown to promote RGC survival in ratmodel of exper-
imental glaucoma [27]. TrkB gene therapy too has the potential to im-
part protection to the RGCs in animal model of ON transection [19].
TrkB involvement in RGC survival is also evident from the fact that use
of highly speciﬁc TrkB agonistic antibodies promotes RGC survival
both in in vitro and in vivo conditions [28,29]. Interestingly, basal
BDNF levels in serum have been reported to be reduced in early stage
glaucoma, though further investigations may be required to conﬁrm
this [30].
Multiple reports from animal studies suggest that glaucoma is
marked by an increase in levels of neurotoxic amyloid β (Aβ) and its ag-
gregation in the inner retina which has been implicated in the develop-
ment of RGC apoptosis in experimental glaucoma. Decreased levels of
Aβ in the vitreous humour (consistent with retinal Aβ deposition)
have also been reported in glaucoma patients [31]. Among various pop-
ulations of Aβ species, Aβ (1–42) has beendemonstrated to exhibit high
toxicity and more prone to deposit formation. Aβ (1–40), the other
major species under physiological conditions, is generally below the de-
tectable limits, considered less toxic and more resistant to aggregation
[32,33]. Enhanced levels of soluble Aβ, in addition to other toxic effects,
may also act by impairing the retrograde trafﬁcking of BDNF and TrkB in
the axons [34], thereby further sequestering its supply.
To investigate the role played by BDNF in preserving the normal
inner retinal environment, this study evaluated for the ﬁrst time poten-
tial biochemical, functional and morphological degenerative changes in
the inner retina of BDNF+/− animals at different ages. The role of BDNF
in mediating glaucoma-induced degenerative changes in the inner reti-
na was determined by overlaying the BDNF+/− mouse model with a
chronicmodel of increased IOP. The results provide novel and important
data on the roles of BDNF impairment in the inner retina under both
physiological as well as pathological conditions. Biochemical observa-
tions including changes in the accumulation of neurotoxic Aβ species
and alterations in the homeostasis of BDNF/TrkB and downstream sig-
nalling pathways in glaucoma were compared with ﬁndings from
human post-mortem tissues. The study was designed primarily to ad-
vance understanding of the role of neurotrophins in glaucoma
pathogenesis but may have relevance to other neurodegenerative con-
ditions associated with BDNF impairment.
2. Materials and methods
2.1. Chemicals
Anti-BDNF (sc-546) and anti-TrkB (sc20542) antibodies were ob-
tained from Santa Cruz Biotechnology (Santa Cruz, CA). pTrkB
(Abcam, ab51187), pAkt (Ser473) (Cell Signaling, 193H12), Akt (Cell
Signaling, 11E7), p44/42 MAPK (Erk1/2) (Cell Signaling, 137F5), p-
p44/42 MAPK (Erk1/2 Thr202/Tyr204) (Cell Signaling D13.14.4E),
GSK-3β (Cell Signalling, 27C10), pGSK-3β (Ser9) (Cell Signaling 5B3)
and β-actin (Sigma, AC-40) antibodies were used for Western blotting.
Human (KHB3441) andmouse Aβ42 (KMB3441) ELISA kits andﬂuores-
cent polystyrene microspheres were obtained from Invitrogen
(FluoSpheres; Invitrogen, Carlsbad, CA). All other reagents were of ana-
lytical grade (Sigma, St. Louis, MO).
2.2. Animals
All procedures involving animals were conducted in accordance
with the Australian code of practice for the care and use of animals for
scientiﬁc purposes and the guidelines of the ARVO statement for the
use of animals in ophthalmic and vision research. BDNF heterozygous
(HET) mice and wild-type (WT) control mice (both male and female)were obtained from Mental Health Research Institute (Parkville, VIC,
Australia) and genotyped using standard PCRmethodology. All animals
were maintained in our vivarium in cyclic light (12 h on; 12 h off; ~300
lx), in an air-conditioned roomwith controlled temperature (21±2 °C)
and with free access to water and rodent chow. Where necessary, the
animals were anaesthetised with an intraperitoneal injection of keta-
mine (75 mg/kg) and medetomidine (0.5 mg/kg). BDNF+/− mice ex-
hibited good health, normal behaviour, and had no visible phenotype
different from normal mice.
2.3. SDS-PAGE, Western blot analysis
Following enucleation of the eyes and retinal dissection, ONH re-
gions of the retina were surgically excised from the retina under a mi-
croscope, lysed in lysis buffer (20 mM HEPES, pH 7.4, 1% Triton X-100,
1 mM EDTA) containing 10 μg/ml aprotinin, 10 μM leupeptin, 1 mM
PMSF and 1 mM NaVO3, 100 mM NaF, 1 mM Na2MoO4 and 10 mM
Na4P2O7. Proteins were resolved by 10% SDS-PAGE and transferred to
PVDF membranes. The blots were washed thrice for 5 min with TTBS
(20 mM Tris–HCl [pH 7.4], 100 mM NaCl, and 0.1% Tween 20) and
blocked with 5% nonfat dry milk powder (Bio-Rad) in TTBS for 1 h at
room temperature. Blots were then incubated with anti-BDNF
(1:1000), anti-TrkB (1:1000), anti-pTrkB (Tyr-) (1:1000), anti-Akt
(1:1000), anti-pAkt (Ser 273) (1:1000), anti-Erk (1:1000), anti-pErk
(1:1000), anti-Gsk3β (1:1000), anti-pGsk3β (1:1000) or anti-actin
(1:5000) either for 1 h (actin) at room temperature or overnight
(for other antibodies) at 4 °C. Actin was used to ensure a comparable
loading was made in each case.
Following primary antibody incubations, immunoblots were incu-
bated with horseradish peroxidase (HRP)-linked secondary antibodies
and after extensive washing, antibody detection was accomplished
with Supersignal West Pico Chemiluminescent substrate (Pierce).
Signals were detected using an automated luminescent image analyser
(ImageQuant LAS 4000, GE Healthcare). Band intensities were quanti-
ﬁed using ImageJ software (NIH, USA).
2.4. Histology
Animals were sacriﬁced with an overdose of anaesthetic and then
perfused transcardiallywith 4%paraformaldehyde. Eyeswereharvested
for light microscopic evaluation, ﬁxed in 4% (w/v) paraformaldehyde,
processed in an automatic tissue processor (Leica, Wetzlar, Germany),
and embedded in parafﬁn. Care was taken to ensure that the orienta-
tions of the eyes were identical by using tissue marking dye and 8-μm
thick sagittal sections of the eye were made using a rotary microtome
(Carl Zeiss, Oberkochen, Germany). Tissues were mounted and subject-
ed to haematoxylin and eosin staining. Three consecutive sections
through the optic disc were used to analyse the number of cells in the
retinal ganglion cell layer (GCL). Cell density in the GCLwas determined
for each eye by counting the number of cells in the GCL over a distance
of 500 μm (100 μm to 600 μm from the edge of the optic disc) for both
superior and inferior retina.
2.5. Aβ42 ELISA
Sandwich antibody ELISAs were performed as described previously
[35,36]. Brieﬂy, ONHswere excised from the retinas, sonicated in buffer
containing 5MguanidineHCl/50mMTris HCl (pH8.0) and incubated in
ice for 3 h. The samples were diluted with cold buffer (PBS containing
0.03% Tween-20, supplemented with protease inhibitor cocktail), and
centrifuged at 16,000 g for 15 min at 4 °C to remove insoluble material.
The supernatant was analysed with a human and mouse Aβ42 ELISA
kits according to the manufacturer's instructions (KHB3481 and
KHB3441, Invitrogen). Optical densities at 450 nm of each well were
read on a microplate reader (BioRad), and Aβ42 concentrations were
determined by comparison with the standard curve. Final guanidine
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tions in homogenates were determined by a BCA kit (Pierce).
2.6. Intra-ocular injections and pressure measurements
A chronic RGC degenerationmodel was established by a producing a
chronic increase of intra-ocular pressure (IOP) in mice by microbead
(Fluospheres, Molecular Probes, 10 μm) injections in the anterior
chamber as reported previously [37,38]. Weekly intraocular injections
(3.6 × 106 microbeads/mL) were made until a sustained increase in
IOP was observed. The contralateral eye was used as control. Eyes
were injected using a 25-μL Hamilton syringe connected to a disposable
33-gauge needle (TSK Laboratory, Tochigi, Japan). All intracameral pro-
cedureswere performedundermagniﬁcation using an operatingmicro-
scope (OPMI Vario S88, Carl Zeiss, Oberkochen, Germany) with care
taken to avoid needle contact with the iris or lens. The needle was
inserted bevel down, tangentially beneath the corneal surface, to facili-
tate self-sealing of the puncture wound. Once the needle tip was
visualised within the anterior chamber, 2 μL microbead solution was
injected. At the end of the procedure, anaesthesia was reversed using
atipamazole (0.75 mg/kg subcutaneous injection, and 0.3% ciproﬂoxa-
cin drops (Ciloxan; Alcon Laboratories, NSW, Australia) and 0.1% dexa-
methasone eye drops (Maxidex, Alcon Laboratories) were instilled in
both eyes. An ointment (Lacri-lube; Allergan, NSW, Australia) was also
applied to protect against corneal drying until the animal recovered.
During anaesthesia and prior to each injection, IOP was measured by
using a handheld electronic tonometer (Icare Tonovet, Helsinki,
Finland). The IOP displayed on the tonometer was the mean of six con-
secutive measurements. Three consecutive IOP readings were obtained
from each eye and the average number was taken as the IOP for that
time point.
2.7. Electroretinography
Electroretinographic (ERG) recordings were performed as described
previously [39]. Animalswere dark-adapted overnight and anaesthetisedFig. 1. Decreased amplitude of pSTR in BDNF+/−mice. A) Average trace of pSTR signal obtaine
lowered amplitude of pSTR in the BDNF+/−mice compared to the WT ones (n = 24; age 5 m
in the GCL density at this time point. D) Quantiﬁcation indicating no signiﬁcant difference w
Scale 50 μm.with ketamine and medetomidine (75 and 0.5 mg/kg, respectively),
and pupils were dilated using 2.5% phenylephrine, after which 1%
tropicamide and topical anaesthetic (1% proparacaine) were applied to
the cornea. Animalswere positioned on aheated sliding stage tomaintain
body temperature during anaesthesia and recording sessions. Ground
and reference electrodeswere placed subcutaneously in the tail and fore-
head of the animal, respectively. A solid custom-made gold ring recording
electrode (Roland Consult, Brandenburg, Germany) was placed on each
eye in contact with the cornea, and a thin layer of methylcellulose was
used tomaintain contact between the cornea and the electrode and tode-
crease the recording noise. ERGs were recorded using a ﬂash intensity of
3 log cd·s/m2 (Ocusciences, Xenotec, Inc., MO, USA). For scotopic thresh-
old responses (STRs) dim stimulation using ﬂash intensities of−3.4 log
cd·s/m2 was delivered 30 times at a frequency of 0.5 Hz. For all positive
STR responses, amplitudes were measured from baseline to the positive
peak observed around 120 ms. For all ERG recordings, a-wave amplitude
was measured from baseline to the a-wave trough; b-wave amplitude
was measured from the a-wave trough to the peak of b-wave.
2.8. Human samples
Freshly frozen humanpost-mortem eye samples from glaucoma and
control human donors were obtained from the Sydney Eye Bank,
Australia. Ethics approval was obtained from the Macquarie University
Human Research Ethics committee. Research was carried out in accor-
dance with the principles outlined in the declaration of Helsinki. Ages
of the tissue donors ranged from 67 to 82 years with a mean of
74 years (SD 7.4 years). A history of glaucoma had been obtained
from the donors medical records.
2.9. Statistical analysis
The ERG/STR responses, cell density in the GCL, amyloid β levels as
well as protein expressions were compared between the experimental
and control groups. Datawere analysed and graphed using commercial-
ly available GraphPad Prism software (version 6.0) (GraphPad Software,d from BDNF+/− (dotted) and WT mice (solid). B) Quantiﬁcation indicates a signiﬁcantly
onths; p b 0.05). C) H and E staining of the retinal sections did not indicate any changes
as observed in the GCL density between WT and BDNF+/− mice at 5 months (n = 4).
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from given n sizes and compared by Student's t test for unpaired data.
The signiﬁcance was set at p b 0.05.3. Results
3.1. BDNF+/− mice exhibit reduced STR amplitudes and GCL thinning as
they age
In order to determine the involvement of BDNF in preservation of
normal inner retinal integrity, the electrophysiological responses
(pSTR) of WT and BDNF+/− mice were evaluated at 5 months of age.
Average pSTR traces from WT and BDNF+/− mice were plotted
(Fig. 1A). BDNF+/−mice depicted a small but statistically signiﬁcant de-
crease in pSTR amplitude compared to the WT animals (n = 24; p
b 0.05) (Fig. 1B). Assessment of the retinal sections of mice stained
with H and E revealed no signiﬁcant differences in the density of cells
in the GCL (n = 4) (Fig. 1C,D). WT and BDNF+/− animals were also
assessed for functional andmorphological differences in the inner retina
at 1 year of age. pSTR amplitudes from BDNF+/− mice were also ob-
served to be smaller compared to their WT counterparts (Fig. 2A).
Quantiﬁcations revealed that although differences appeared to be
small, signals from BDNF+/−mice were statistically signiﬁcantly lower
than the age-matchedWT animals (n=12; p b 0.003) (Fig. 2B). A com-
parison of the pSTR amplitudes from BDNF+/− mice at 5 months and
1 year indicated that pSTR amplitudes of BDNF+/− mice at 1 year
were slightly but statistically signiﬁcantly lower compared to those at
5 months of age (p b 0.05) indicating that there is an age-dependent
progressive decline in inner retinal function (Fig. 2C). The retinal histo-
logical sections showed a signiﬁcant decrease in the density of cells in
the GCL in BDNF+/− mice at the 1 year time point (n = 4; p b 0.05)
(Fig. 2D,E). These results indicate that BDNF plays an important role in
protecting the inner retina against functional and structural deteriora-
tion with age. An evaluation of the whole retinal scotopic electrophysi-
ological response and quantiﬁcation of the a- and b-wave amplitudes
indicated no signiﬁcant changes (n = 8) between the WT andFig. 2. Progressive degenerative changes in the inner retina in BDNF+/− mice. A) Average
B) Quantiﬁcation indicates a signiﬁcantly lowered pSTR amplitude in the BDNF+/− mice (n
BDNF+/−mice at 5 month and 1 year time points (p b 0.05). D) Retinal sections stained wit
year of age. E) Quantiﬁcation indicating signiﬁcant differences was observed in the GCL densitBDNF+/− mice at either 5 months (Fig. 3A,B) or 1 year (Fig. 3 C,D).
This indicated that BDNF might be playing a more speciﬁc role in the
preservation of inner retinal function. A comparison of the intraocular
pressure (IOP) between the WT and BDNF+/− mice at 2 months,
5 months and 1 year revealed that it remained similar between the
two groups, indicating that observed functional and structural differ-
ences could not be attributed to exposure of the eyes to possibly differ-
ent IOPs (Fig. 3E).
3.2. BDNF+/−mice exhibit enhanced levels of soluble Aβ (1–42) in the ONH
with age
Increased Aβ accumulation in the RGCs has been implicated in their
progression to apoptosis in experimental glaucoma [40]. The Aβ (1–42)
levels in the ONH of both WT and BDNF+/−mice were assessed at dif-
ferent time points to determine the role of BDNF in mediating changes
in Aβ levels in the retina. Results indicated that under normal physio-
logical conditions the levels of soluble Aβ (1–42) were fairly uniform
at 2 and 5 month time points. However, therewas an increase in soluble
Aβ (1–42) levels at 1 year time point. This increase was signiﬁcantly
more in BDNF+/− mice than that caused by age-induced changes in
the Aβ levels in WT controls (n= 8; p b 0.01) (Fig. 4). This experiment
indicated that BDNF impairment contributed to progressive accumula-
tion of neurotoxic Aβ (1–42) species in the ONH. Interruption of BDNF
signalling has previously been shown to rapidly activate amyloidogenic
pathways and exacerbate Aβ production causing neuronal apoptotic
death in the hippocampal neurons [41].
3.3. BDNF+/− mice are more susceptible to inner retinal degenerative
changes caused by glaucoma
As BDNF+/−mice are more inclined to degenerative changes in the
inner retina caused by age under normal IOP, we investigated whether
exposure to high IOP exacerbates the severity of these changes. WT an-
imals were exposed to high IOP (8 weeks) and pSTR electrophysiologi-
cal recordings carried out (Fig. 5A). Analysis indicated a signiﬁcanttrace of pSTR signal from the BDNF+/− (dotted) and WT ones (solid) at 1 year of age.
= 12; p b 0.003). C) Graph showing a comparative analysis of the pSTR amplitudes in
h H and E show a thinning of the GCL in the retinal cross-sections in BDNF+/−mice at 1
y between WT and BDNF+/−mice at this time point (n = 4; p b 0.05). Scale 50 μm.
Fig. 3. Changes in scotopic ERG recordings and intraocular pressure between WT and BDNF+/−mice with age. Average ERG traces of WT and BDNF+/−mice at A) 5 months and B) the
quantiﬁcation of a- and b-wave amplitudes. C) Average ERG trace at 1 year of age and D) graphical representation of the amplitudes of the a- and b-waves respectively (n = 8).
E) IOPs were not observed to be altered to any signiﬁcant extent in BDNF+/−mice at any time point compared to their wild type counterparts.
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BDNF+/− animals to high IOP (8 weeks) also resulted in a notable de-
cline in the IOP amplitudes (n = 7; p b 0.002) (Fig. 5C,D). Comparison
revealed that there was a signiﬁcantly higher loss in the pSTR ampli-
tudes in BDNF+/− mice compared to the WT counterparts (p b 0.04)
(Fig. 5E). This experiment highlighted the role of BDNF in protecting
the inner retinal function in animals exposed to high IOP. Whether
these functional observations were accompanied by morphological
changes in the inner retina was assessed by H and E staining of the ret-
inal sections. The GCL was much thinner in the eyes exposed to in-
creased IOP in both the WT (Fig. 5F,G) as well as the BDNF+/−
(Fig. 5H,I) animals. Quantiﬁcation revealed a signiﬁcant decline in the
number of cells in the GCL in the WT (n = 4; p b 0.02) (Fig. 5J) as
well as BDNF+/− (n = 4; p b 0.001) (Fig. 5K) animals. The decrease in
GCL cell density was however much pronounced in the BDNF+/− ani-
mals exposed to a similar range of high IOP compared to the WT coun-
terparts (n = 4; p b 0.03) (Fig. 5L). Evaluation of the changes in IOP
caused by microbead injections over an 8 week period revealed that
the increase in IOP was comparable and both the WT and BDNF+/−
mice were largely exposed to a similar sustained increase in IOP
(23.71 ± 3.78 mm Hg for WT and 23.9 ± 3.65 mm Hg for BDNF+/−)Fig. 4. Accumulation of neurotoxic Aβ (1–42) species in the ONH. Evaluation of levels of
soluble Aβ (1–42) indicate its signiﬁcantly enhanced concentration in ONH of BDNF+/−
mice compared to the WT counterparts at 1 year time point (p b 0.01). No signiﬁcant
changes were observed in Aβ (1–42) levels at either 2 or 5 months of age (n = 5).from a baseline IOP of 10.84 ± 0.3 mm Hg (Fig. 6A,B). The evaluation
of the whole retinal scotopic electrophysiological response and quanti-
ﬁcation of the a- and b-wave amplitudes indicated no change in the av-
erage a-wave but a slight decline in average b-wave amplitudes in
both WT (Fig. 6C) and BDNF+/− (Fig. 6D) animals exposed to high IOP
(n = 8). However these changes were not found to be statistically sig-
niﬁcant (Fig. 6E,F). This indicated that BDNF might be playing a more
speciﬁc role in the preservation of inner retinal function. Overall, these
experiments indicate that BDNF heterozygosity pre-disposes the ani-
mals to glaucoma-induced functional and structural changes localised
mainly to the inner retina.
3.4. BDNF/TrkB signalling in ONH is negatively affected in glaucoma
We evaluated changes in the levels of BDNF in the ONH of WT and
BDNF+/− mice at 5 months (Fig. 7A) and 1 year (Fig. 7C) time points
usingWestern blotting. Densitometric evaluation of the bands revealed
no signiﬁcant alterations in BDNF levels at 5 months (Fig. 7B) but statis-
tically signiﬁcant down regulation of BDNF availability (decrease of
21.33 ± SD 5%) at 1 year time point in BDNF+/− mice (n = 3; p
b 0.006) (Fig. 7D). Exposure to elevated IOP (8w) led to a reduction in
the BDNF levels in the ONH in both WT and BDNF+/− animals
(Fig. 7E). The decline in BDNF in response to exposure to increased
IOP was greater in the case of BDNF+/− (p b 0.001) compared to the
WT animals (p b 0.05) (n = 4). The percentage decrease in reactivity
upon exposure to high IOP was much higher in BDNF+/− mice com-
pared to the WT counterparts (30.0 ± SD 12.73% for WT and 65.5 ±
SD 4.95% for BDNF+/−mice) (Fig. 7F).
We investigated whether alterations in BDNF levels lead to changes
in TrkB and downstream survival signalling pathways in glaucoma.
The ONH tissues from the control and high IOP exposed WT (Fig. 8A)
(n = 3) as well as BDNF+/− (Fig. 8G) (n = 4) animals were subjected
to Western blotting. Analysis and densitometric quantiﬁcation of the
signals revealed that in accordance with the reduced BDNF availability,
there is a reduced phosphorylation of TrkB receptor in both the WT
(Fig. 8B) and BDNF+/− (Fig. 8H) mice. A decreased activation of Akt
and Erk1/2 which are downstream survival signalling molecules of
TrkB receptor, was observed in the ONH of both the WT (Fig. 8C–E)
Fig. 5. BDNF+/− mice are more susceptible to loss in pSTR amplitude and in GCL density in response to increased IOP. A) Traces of pSTR from control WT mice and mice exposed to
increased IOP B) Quantiﬁcation highlighting a decrease in pSTR amplitude in high IOP exposed animals (n = 5; p b 0.02). C) pSTR traces obtained from control BDNF+/− mice and
BDNF+/−mice exposed to increased IOP. D) Quantiﬁcation of the pSTR amplitudes indicating a sharp decline in pSTR amplitudes in high IOP exposed BDNF+/−mice compared to the
controls (n=7; p b 0.002). E) Graph indicating that a greater loss in pSTR amplitudes is observed in BDNF+/−mice upon exposure to increased IOP compared to WT counterparts
(p b 0.04). F–I) H and E stained retinal sections fromWT and BDNF+/−mice showing a decrease in GCL density in high IOP exposed animals. J–K) Quantiﬁcations of the cells in
GCL indicating a decline in GCL density in both WT (n = 4; p b 0.02) and BDNF+/− (n = 4; p b 0.001) mice when exposed to high IOP. L) A signiﬁcantly reduced number of cells
were observed in BDNF+/− mice exposed to high IOP compared to the WT counterparts (n = 4; p b 0.03). Scale 50 μm.
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also observed a decline in the phosphorylation status of the GSK3β
(Ser9) which is downstream of PI3k/Akt pathway for both the WT and
BDNF+/− animals exposed to high IOP (Fig. 8F,L). No signiﬁcant changes
were observed in the expression levels of either total TrkB, Akt, Erk1/2
or GSK3β proteins. These data indicate that BDNF/TrkB signalling is
negatively affected in glaucoma and that the downregulation is
compounded further in the BDNF+/−mice.
In order to correlate these ﬁndings with the pathological changes ob-
served in human glaucoma, the ONH tissues from fresh post-mortem
human eye donor tissues from glaucoma subjects (age 73.75 years, SD7.2 years) were analysed by Western blotting and compared with age-
matched controls (n=4) (74.5 years, SD 8.6 years). ONHwas surgically
dissected out from retina, lysed, subjected to Western blotting and
probed with antibodies against BDNF, pTrkB, TrkB, pAkt, Akt, pErk1/2,
Erk1/2, Gsk3β and pGsk3β proteins and actin (Fig. 9A). Similar to that
observed in animal models of glaucoma, densitometric quantiﬁcation
of the band intensities revealed the presence of decreased levels of
BDNF in the ONH of glaucoma subjects (p b 0.03) (Fig. 9B). A corre-
sponding decline in the phosphorylation of TrkB, Akt, Erk 1/2 and
GSK3β proteins was also observed (Fig. 9B). No signiﬁcant changes in
the expression of either of TrkB, Akt, Erk1/2 or Gsk3β proteins were
Fig. 6. IOP and scotopic ERG changes in WT and BDNF+/−mice with repetitive injections of microbeads (8 weeks). A comparable increase in IOP was observed between the A) WT and
B) BDNF+/−mice after anterior chamber injections. Average ERG traces of C)WT control and high IOP exposedmice andD) BDNF+/− control and high IOP exposedmice respectively. E–F)
Quantiﬁcations indicating that no statistically signiﬁcant changeswere observed in either a- or b-wave amplitudes inWT or BDNF+/− groups exposed to chronically increased IOP (n=8).
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stream pro-survival signalling in the ONH is directly affected in animal
models of experimental glaucoma as well as in tissues obtained from
post-mortem glaucoma subjects.3.5. Glaucoma is associated with enhanced levels of soluble Aβ (1–42)
in the ONH
We observed an increase in the concentration of soluble Aβ (1–42)
in the ONH of both WT (p b 0.002) (Fig. 10A) and BDNF+/− (p
b 0.001) (Fig. 10B) mice exposed to chronically increased IOP using
microbead injections, compared to the corresponding controls (n = 4)
(Fig. 10A,B). There was, however, a greater accumulation of Aβ (1–42)
in the ONH samples from BDNF+/−mice compared to theWT counter-
parts exposed to similarly raised IOP (p b 0.005) (Fig. 10C). These data
indicate that exposure to glaucoma induces a build-up of neurotoxic
Aβ (1–42) species in ONH and this increase is further exacerbated
with BDNF impairment. The alterations in Aβ (1–42) levels in ONH in
glaucoma may thus be a combined effect of decreased availability of
BDNF levels, loss of TrkB and its downstream signalling, and increased
intraocular pressure. High IOP exposure caused a greater elevation in
Aβ levels in both the WT and BDNF+/− animals (Fig. 10C) compared
to that induced by effect of age (WT p b 0.01; BDNF+/− p b 0.001)
(Fig. 4). These ﬁndings in an animal model of glaucomawere substanti-
ated upon analysis of human ONH tissues from glaucoma and control
subjects. ELISA assays revealed that levels of soluble Aβ (1–42) species
were consistently and signiﬁcantly increased in the ONH samplesderived from glaucoma subjects (n = 4; p b 0.01) compared to the
age matched controls (Fig. 10D).
4. Discussion
Our study conﬁrmed that BDNF plays an important role in the pres-
ervation of inner retinal integrity in health and disease conditions. An
interruption of BDNF transport along the ON axons has been proposed
to be responsible for RGC death in various models of optic nerve injury
including glaucoma. The role of BDNF in preserving the inner retinal
function and morphology was evaluated by following the BDNF+/− an-
imals at various ages. A moderate decline in inner retinal function indi-
cated by changes in pSTR amplitudes was evident initially at around
5 months of age (Fig. 1A,B). Interestingly, these functional changes
were not accompanied by corresponding changes in the structure or
cell density of the inner retina (Fig. 1C,D). Follow-up of the animals at
the 1-year time point depicted a further decline in the amplitudes of
electrophysiological recordings representing inner retinal function
(Fig. 2A–C). Analysis of the retinal sectionmorphology revealed a reduc-
tion in the density of GCL at this time point (Fig. 2D,E). Together, these
ﬁndings suggested that BDNF impairment can have a progressive age-
related detrimental effect on the function of the inner retina. No signif-
icant differences in the scotopic ERG recordings (Fig. 3A–D) or IOPs
(Fig. 3E) were observed from these mice at any of the time points.
The degenerative changes derived from the BDNF heterozygosity
eventually translated into a phenotype depicting reduction of cells in
the GCL at 12 months. Previous reports have shown that BDNF was
not required for RGC survival during development [42], so these mice
Fig. 7. Changes in BDNF levels in the ONH tissue with age and upon exposure to elevated IOP. A)Western blot analysis of BDNF levels in the ONH tissues fromWT and BDNF+/−mice at
5 months of age. B) Densitometric quantiﬁcation of the bands from (A) indicates no signiﬁcant differences in the levels of BDNF (n=3). C) Decreased BDNF levelswere detectable in ONH
of BDNF+/−mice at 1 year time point. D)Densitometric quantiﬁcation of bands from (C) indicates signiﬁcant downregulation of BDNF levels in theBDNF+/−mice compared toWT animals
(n= 3; p b 0.006). E–F). Exposure to high IOP (8 weeks) leads to decrease in BDNF levels in the ONH of both theWT and BDNF+/−mice (n = 4). Densitometric quantiﬁcation revealed
greater decline in BDNF levels in BDNF+/−mice (p b 0.001) compared to the WT counterparts (p b 0.05). Actin was used as loading control.
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can then be monitored over time. This study, together with several
in vitro and in vivo experimental lesion models supports the notion
that BDNF plays a critical role in promoting the survival of RGCs.
At themolecular level, increased Amyloid immunoreactivity, mainly
localised to the GCL and inner nuclear layer, has previously been impli-
cated in the development of RGC apoptosis [40,43,44]. Intravitreal injec-
tions of Aβ (1–42) have been reported to exhibit chronic toxicity to
retinal neurons [45]. Evaluation of alterations in Aβ (1–42) concentra-
tions in the ONH revealed that soluble Aβ (1–42) levels stayed fairly
constant in the WT and BDNF+/− mice at 2 and 5 months of age, but
were signiﬁcantly enhanced in the BDNF+/−mice at 1 year indicating
it to be a progressive degenerative effect which manifested itself with
age (Fig. 4). Loss of BDNF signalling in hippocampal neurons has previ-
ously been shown to lead to enhanced Aβ production causing neuronal
apoptotic death [41]. The role of BDNF in regulatingAβhomeostasiswas
further supported by the fact that exogenous application of BDNF in the
hippocampus leads to a reduction in levels of Aβ [46]. Treatment of cul-
tured hippocampal neuronswith anti-BDNF antibodies leading to its se-
questration induced amyloidogenic processing in these cells [47]. BDNF
decrease has also been shown to have a role in the accumulation of Aβ
in Alzheimer's disease (AD). BDNF polymorphisms such as Val66Met
and Cys270Thr, were found to be associatedwith an increased risk of de-
veloping AD [48,49]. In retina, we believe that BDNF impairment pro-
moted a gradual accumulation of neurotoxic Aβ (1–42) in the ONH
eventually leading to loss of neurons in the GCL. Aβ deposits were also
shown to accumulate with age in the inner retina and nerve ﬁbre
layer of transgenic mouse models of AD in previous studies [50]. Aβ ac-
cumulation may further aggravate BDNF/TrkB deﬁcits by impairing the
retrograde trafﬁcking of BDNF and TrkB from the ON axons [34].The higher susceptibility of BDNF+/−mice to development of neuro-
degenerative changes in the inner retina with age indicates that these
may be more pre-disposed to glaucoma-induced deﬁcits in the retina
and ONH. The role of BDNF in glaucoma was investigated by exposing
the BDNF+/− and WT mice to a comparable and chronically increased
IOP (Fig. 6A,B). A signiﬁcantly higher reduction in pSTR amplitudes
was observed in BDNF+/− mice upon exposure to increased IOP for
8 weeks, compared to the WT ones (Fig. 5A–E). Absence of signiﬁcant
changes in the whole retinal scotopic ERG recordings indicated that
these changes were predominantly localised to the inner retina
(Fig. 6C–F). A corresponding decline in GCL density was also evident
upon evaluation of the morphology of retinal sections (Fig. 5J,K). The
decline was greater in the BDNF+/− mice compared to the WT mice
(Fig. 5L). BDNF+/− mice thus depicted an inner retinal degeneration
phenotype when stressed with a chronic exposure to increased IOP. A
higher vulnerability of BDNF+/− mice to degenerative changes in the
inner retina caused by elevated IOP may in part, be attributed to possi-
ble underlying developmental changes subsequent to BDNF insufﬁcien-
cy. Alternatively, these effects may possibly arise from exacerbation of
the BDNF deﬁcit in the inner retina upon exposure to high IOP in
BDNF+/−mice. These deﬁcits may be aggravated by obstruction of the
retrograde supply of BDNF/TrkB from the ON axons by high IOP and de-
creased BDNF/TrkB signalling.
Amyloidβ peptide is a likelymediator of high IOP-induced RGC death
in experimental glaucoma as neutralising antibodies to Aβ signiﬁcantly
reduced the RGC apoptosis [51]. Evaluation of soluble Aβ (1–42) levels
in both the ONH tissues fromWT and BDNF+/− animals indicated a sig-
niﬁcant increase when these were exposed to chronically increased IOP
(Fig. 10A,B). Previously, in a DBA/2J mouse model which develops
glaucomatous changeswith age, increasedAPP andAβ immunoreactivity
Fig. 8.Western blots showing a downregulation of TrkB and downstream signalling in theONHofWT and BDNF+/−mice exposed to high IOP. A)ONH tissue fromWTmice depict reduced
phosphorylation of TrkB, Akt, Erk1/2 and GSK3βmolecules (n= 3). B–F) Densitometric quantiﬁcations indicating a downregulation of TrkB and its downstream signalling in the ONH of
WT mice exposed to high IOP. pTrkB/TrkB (p b 0.003); pAkt/Akt (p b 0.002); pErk1/Erk1 (p b 0.03); pErk2/Erk2 (p b 0.02); pGsk3β/Gsk3β (p b 0.02). G) A greater decline in TrkB
phosphorylation was observed in the BDNF+/− mice with IOP increase compared to the WT counterparts (n = 4). H–L) Densitometric quantiﬁcations depicting downregulation of
TrkB and downstream signalling. pTrkB/TrkB (p b 0.03); pAkt/Akt (p b 0.04); pErk1/Erk1 (p b 0.03); pErk2/Erk2 (p b 0.02); pGsk3β/Gsk3β (p b 0.02). No signiﬁcant changes were
observed in the expression of the total TrkB, Akt, Erk or Gsk3β proteins. Actin was used as loading control.
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levels however was much more pronounced in the BDNF+/−mice com-
pared to the WT mice indicating that BDNF has a role in Aβ production,
metabolism or its clearance (Fig. 10C). In this aspect Aβ pathology in
glaucoma appears analogous to that observed in AD, supported by the
fact that a reduced BDNF expression was also observed in the brains of
AD patients [47,53,54]. BDNF infusion or over-expression in the brain
was shown to reverse neuronal atrophy and synaptic loss associated
with AD and ageing in animals [55]. However, it remained unclear
whether enhanced β amyloidogenesis observed in the ONH of aged
BDNF+/−mice was directly caused by loss of BDNF or an effect of some
other molecular degenerative changes associated with BDNF heterozy-
gosity. The observations on Aβ levels from animal models of experimen-
tal glaucoma were supported by results obtained from the human ONH
tissues. We observed a consistent increase in the levels of soluble Aβ
(1–42) in the ONH of human glaucoma samples compared to the age-
matched controls, suggesting alterations in Aβ (1–42) as an important
component of glaucoma pathology (Fig. 10D).BDNF loss has previously been shown to be associated with de-
creased activation of TrkB and downstream pro-survival signalling
pathways [56]. Evaluation of changes in BDNF availability in the ONH
caused by exposure to increased IOP revealed that BDNF levels were
much lower in the experimental glaucoma conditions compared to
the controls (Fig. 7E). The decrease in BDNF immunoreactivity was
much greater in the ONH from BDNF+/−mice indicating that possible
high IOP mediated obstruction has more severe effect on the BDNF
availability in these animals due to their already impaired BDNF status
(Fig. 7F). We observed a decreased TrkB phosphorylation in both the
WT and BDNF+/− animals subjected to increased IOP in accordance
with reduced BDNF levels (Fig. 8B,H). Evaluation of downstream Akt
and Erk signalling indicated a deactivation of these pro-survival mole-
cules in the ONH. The loss of activation was more pronounced in
BDNF+/− mice compared to WT ones for both of these molecules
(Fig. 8C–E, I–K). Interestingly, we observed a downregulation of the
GSK3β (Ser 9) phosphorylation, which is generally downstream of
PI3K/Akt pathway, indicating its activation (Fig. 8F,L). GSK3β activation
Fig. 9. BDNF/TrkB signalling is negatively affected in glaucoma. A) ONH tissues from human control and glaucoma post-mortem eyes were surgically excised under themicroscope, lysed
and samples subjected to western blotting and probed with respective antibodies (n = 4 each). Actin was used as the loading control. B) Quantiﬁcation revealed a signiﬁcant decline in
expression of BDNF (p b 0.03) as well as the activation of pTrkB/TrkB (p b 0.05), pAkt/Akt (p b 0.05), pErk1/Erk 1 (p b 0.03), pErk2/Erk2 (p b 0.02), pGsk3β/Gsk3β (p b 0.005) signalling.
No signiﬁcant alterations in expression of TrkB, Akt, Erk1/2 or Gsk3β proteins were observed.
Fig. 10. Glaucoma induces an increase in Aβ (1–42) levels in ONH which is exacerbated
in the BDNF+/− mice. ELISA indicating enhanced soluble Aβ (1–42) levels in ONH
upon exposure to increased IOP in both A) WT; p b 0.002 and B) BDNF+/− p b 0.001
mice (n = 4 each). C) Comparison showing that Aβ (1–42) accumulation is signiﬁcantly
greater in BDNF+/− mice compared to WT group exposed to high IOP (p b 0.005).
D) Levels of soluble Aβ (1–42) are signiﬁcantly greater in the ONH of post-mortem
samples obtained from glaucoma subjects compared to controls (n = 4; p b 0.01).
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tions involving loss of growth factors, PI3K/Akt inhibition and Aβ in-
duced toxicity [57]. In order to corroborate the relevance of these
ﬁndings with human glaucoma, we evaluated the ONH tissues obtained
from post-mortem donors with age-matched controls. BDNF levels
were observed to be signiﬁcantly and consistently down-regulated in
theONHof glaucoma subjects (Fig. 9A,B). The loss of BDNFwas reﬂected
in the decreased TrkB activation and also a further decreased activation
of the downstream Akt and Erk1/2 pro-survival signalling molecules
[18,19]. The activation of GSK3βwas also observed in the human tissues
obtained from glaucoma subjects (Fig. 9A,B). Gsk3β is a key protein in-
volved in neuronal survival and has been regarded as a convergingpoint
for NMDA, P2X7 and BDNF receptor signalling [58]. Interestingly, Aβ is
also known to promote GSK3β activation and experimentally inhibiting
the Gsk3β activity suppresses the toxic effects of Aβ [57]. To our knowl-
edge, this is theﬁrst report highlighting the association of GSK3β activa-
tion in glaucoma. The decrease in BDNF availability and loss of
downstream BDNF/TrkB signalling may eventually translate into func-
tional and structural degenerative changes observed in the high IOP ex-
posed animals. Exacerbation of these changes in BDNF+/−micemay be
due to their exposure tomuch reduced BDNF availability and greatly re-
duced BDNF/TrkB signalling.
In summary, BDNF/TrkB and downstream signalling are affected in
the inner retina and ONH in glaucoma, leading to degenerative changes
manifested in the form of accumulation of soluble Aβ and decline in
inner retinal function and GCL thinning. The involvement of BDNF in
glaucoma is evident from the fact that BDNF heterozygosity makes the
retinas and ON more susceptible to glaucomatous damage and aggra-
vates the glaucomatous deﬁcits in an experimentalmodel. Degenerative
changes similar to those observed in glaucoma are also observed in the
retina and ON in normal BDNF+/−mice with age. As an important fu-
ture direction, inducible cremediated acute knock down of BDNF will
1577V. Gupta et al. / Biochimica et Biophysica Acta 1842 (2014) 1567–1578further help to deﬁne its role in maintaining RGC function and survival
under both health and disease conditions. Overall, these results support
the hypothesis that chronic loss of neurotrophic actions of BDNF and its
signallingmay be an importantmechanismunderlying the ganglion cell
and optic nerve degenerative changes.Acknowledgements
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